We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Urinary Method Detects Toxin Exposure from Harmful Algal Blooms

By LabMedica International staff writers
Posted on 29 Jan 2020
During harmful algal blooms (HABs), species of cyanobacteria release toxic peptides, including microcystins and nodularin into waterways, impacting wildlife and humans living in these marine environments.

Human exposure comes from ingestion, direct skin contact, or inhalation and can lead to a variety of symptoms ranging from gastroenteritis, nausea, allergic reactions and skin rashes to hepatic injury and hemorrhage in more severe cases. More...
Microcystins also have been linked to tumor progression and are harmful to renal, immune and reproductive systems.

A group of scientists led by the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) tested a newly developed immunocapture protein phosphatase inhibition assay (IC-PPIA) method for detection of microcystins and nodularin in human urine. This method uses a commercially available antibody to specifically isolate microcystins and nodularine from human urine prior to measurement. Urines from the Florida residents were self-collected by participants into sterile collection cups and stored at −80 °C until shipment to the Florida Atlantic University laboratory (Ft. Pierce, FL, USA).

The team used the Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) to measure peak areas from the samples. The highly toxic MC congener microcystin-LR was resolved on an Agilent 1290 liquid chromatograph (Agilent Technologies, Santa Clara, CA, USA) using an Acquity UPLC BEH C18 column (Waters, Milford, MA, USA). A Protein Phosphatase Inhibition Assay was performed and the absorbance was read at 405 nm on a Powerwave HT microplate spectrophotometer (BioTek, Winooski, VT, USA).

The scientists demonstrated that the IC-PPIA method developed by the CDC was able to detect low-dose human exposures to microcystins by analysis of urine from three of the 86 urine specimens analyzed by this new method, which yielded positive results with concentrations of 0.055, 0.089 and 0.052 ng/mL MC-LR equivalents. These findings are the first to report microcystin concentrations directly from exposed residents impacted by cyanobacteria in Florida.

The authors concluded that they had described the development and application of an IC-PPIA for detection of nearly all microcystins (MCs) and nodularin (NOD) in human urine. Ten-fold sample concentration in this method makes it sensitive enough to detect even low-level human inhalation exposures to MCs and NOD. This method could complement water monitoring programs by identifying human exposures to MCs and NOD at the time of HABs and may assist in elucidating health effects associated with these toxins in the future. The study was published on December 19, 2019 in the journal Toxins.

Related Links:
Centers for Disease Control and Prevention
Florida Atlantic University
Thermo Fisher Scientific
Agilent Technologies
BioTek
Waters



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.